Interstitial lung disease in microscopic polyangiitis and granulomatosis with polyangiitis: demographic, clinical, serological and radiological features of an Italian cohort from the Italian Society for Rheumatology.

OBJECTIVES Interstitial lung disease (ILD) has been described as a possible pulmonary involvement in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitides (AAV), mainly granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Aim of this cross-sectional Italian national study was to describe demographic, clinical and serological profile of ILD related to MPA and GPA and investigate possible correlations between radiologic patterns of ILD and vasculitis features. METHODS We enrolled 95 consecutive patients with AAV-ILD, 56 affected by MPA (58.9%) and 39 by GPA (41.1%). RESULTS NSIP was the most frequently detected ILD pattern, observed in c-ANCA patients in 60.9% of cases, followed by UIP pattern mainly observed in p-ANCA patients (47.7%, p=0.03). ILD represented the first clinical manifestation, preceding vasculitis diagnosis in 22.1% of cases and, globally, ILD was already detectable at AAV diagnosis in 66.3% of patients. The diagnosis of ILD preceded that of AAV in 85.7% of p-ANCA positive-patients, while only one patient with c-ANCA developed ILD before AAV (p= 0.039). Multivariate analysis confirmed the correlation of UIP pattern with p-ANCA-positivity and a diagnosis of ILD before AAV, also when adjusted for age and sex. CONCLUSIONS Our study confirms that UIP is a frequent pattern of lung disease in AAVILD patients. Our results also suggest that ILD can represent an early complication of AAV but also occur in the course of the disease, suggesting the need of a careful evaluation by both pulmonologist and rheumatologist to achieve an early diagnosis. Further prospective studies are needed to define ILD prevalence and evolution in AAV patients.

[1]  P. Merkel,et al.  2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis , 2022, Annals of the Rheumatic Diseases.

[2]  P. Merkel,et al.  2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis , 2022, Annals of the Rheumatic Diseases.

[3]  B. Collins,et al.  Diagnosis and Management of Fibrotic Interstitial Lung Diseases. , 2021, Clinics in chest medicine.

[4]  E. Bargagli,et al.  Interstitial Lung Disease and Anti-Myeloperoxidase Antibodies: Not a Simple Association , 2021, Journal of clinical medicine.

[5]  F. Ferro,et al.  One year in review 2021: systemic vasculitis. , 2021, Clinical and experimental rheumatology.

[6]  L. Richeldi,et al.  An updated safety review of the drug treatments for idiopathic pulmonary fibrosis , 2021, Expert opinion on drug safety.

[7]  M. Wislowska,et al.  Subphenotypes of ANCA-associated vasculitis identified by latent class analysis. , 2020, Clinical and Experimental Rheumatology.

[8]  N. Sverzellati,et al.  Epidemiology and management of interstitial lung disease in ANCA-associated vasculitis. , 2020, Clinical and experimental rheumatology.

[9]  Kevin McCarthy,et al.  Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement , 2019, American journal of respiratory and critical care medicine.

[10]  L. Corral-Gudino,et al.  The complexity of classifying ANCA-associated small-vessel vasculitis in actual clinical practice: data from a multicenter retrospective survey , 2019, Rheumatology International.

[11]  Augustine S. Lee,et al.  Interstitial Lung Disease and Other Pulmonary Manifestations in Connective Tissue Diseases , 2019, Mayo Clinic proceedings.

[12]  Jong Sun Park,et al.  Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases , 2018, European Respiratory Review.

[13]  A. Ishizu,et al.  Pathogenesis and therapeutic interventions for ANCA-associated vasculitis , 2018, Nature Reviews Rheumatology.

[14]  D. Lynch,et al.  Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. , 2017, The Lancet. Respiratory medicine.

[15]  K. Mortensen,et al.  Pulmonary Involvement in Antineutrophil Cytoplasmic Antibodies (ANCA)-associated Vasculitis: The Influence of ANCA Subtype , 2017, The Journal of Rheumatology.

[16]  C. Kallenberg,et al.  Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis , 2017 .

[17]  M. Alba,et al.  Interstital lung disease in ANCA vasculitis. , 2017, Autoimmunity reviews.

[18]  Julie K. Watson,et al.  Anti-myeloperoxidase antibodies attenuate the monocyte response to LPS and shape macrophage development , 2017, JCI insight.

[19]  D. Cornec,et al.  ANCA-associated vasculitis — clinical utility of using ANCA specificity to classify patients , 2016, Nature Reviews Rheumatology.

[20]  Rohit Sharma Revised International Chapel Hill Consensus Conference nomenclature of vasculitides , 2016, Radiopaedia.org.

[21]  N. Inui,et al.  Clinical Implication of Proteinase-3-antineutrophil Cytoplasmic Antibody in Patients with Idiopathic Interstitial Pneumonias , 2016, Lung.

[22]  D. Lynch,et al.  An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features , 2015, European Respiratory Journal.

[23]  Katherine Spinks,et al.  The diagnosis and management of interstitial lung diseases , 2015, BMJ : British Medical Journal.

[24]  K. Nitta,et al.  Pulmonary involvements of anti-neutrophil cytoplasmic autoantibody-associated renal vasculitis in Japan. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[25]  B. Chowdhury,et al.  Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib. , 2015, The New England journal of medicine.

[26]  H. Yamanaka,et al.  Interstitial Lung Disease with ANCA-associated Vasculitis , 2015, Clinical medicine insights. Circulatory, respiratory and pulmonary medicine.

[27]  P. Grenier,et al.  Pulmonary Fibrosis in Antineutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis , 2014, Medicine.

[28]  C. Kallenberg Key advances in the clinical approach to ANCA-associated vasculitis , 2014, Nature Reviews Rheumatology.

[29]  Shandra L. Protzko,et al.  An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. , 2013, American journal of respiratory and critical care medicine.

[30]  E. Miyazaki,et al.  Incidence of myeloperoxidase anti-neutrophil cytoplasmic antibody positivity and microscopic polyangitis in the course of idiopathic pulmonary fibrosis. , 2013, Respiratory medicine.

[31]  Yichun Hu,et al.  Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. , 2012, Arthritis and rheumatism.

[32]  Sandrine Katsahian,et al.  Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis , 2012, Annals of the rheumatic diseases.

[33]  T. Colby,et al.  Clinical Significance of Serum Autoantibodies in Idiopathic Interstitial Pneumonia , 2012, Journal of Korean medical science.

[34]  D A Bloch,et al.  The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. , 2010, Arthritis and rheumatism.

[35]  Kazuo Suzuki,et al.  A Comparison of the Clinical Features of ANCA-Positive and ANCA-Negative Idiopathic Pulmonary Fibrosis Patients , 2008, Respiration.

[36]  David Steven Scott,et al.  Modification and validation of the Birmingham Vasculitis Activity Score (version 3) , 2008, Annals of the rheumatic diseases.

[37]  V. Cottin,et al.  ANCA-associated lung fibrosis: analysis of 17 patients. , 2008, Respiratory medicine.

[38]  Min Chen,et al.  Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis in Older Patients , 2008, Medicine.

[39]  D. Scott,et al.  Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies , 2006, Annals of the rheumatic diseases.

[40]  D. Lynch,et al.  Rheumatoid arthritis-related lung diseases: CT findings. , 2004, Radiology.

[41]  B. Bonnotte,et al.  Usual interstitial pneumonia in ANCA-associated vasculitis: A poor prognostic factor. , 2019, Journal of autoimmunity.

[42]  P. Merkel,et al.  2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.